Biogen Inc (BIIB)
202.13
+8.95
(+4.63%)
USD |
NASDAQ |
Apr 24, 16:00
202.99
+0.86
(+0.43%)
After-Hours: 20:00
Biogen Revenue (Quarterly): 2.386B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.386B |
| September 30, 2023 | 2.530B |
| June 30, 2023 | 2.456B |
| March 31, 2023 | 2.463B |
| December 31, 2022 | 2.544B |
| September 30, 2022 | 2.508B |
| June 30, 2022 | 2.589B |
| March 31, 2022 | 2.532B |
| December 31, 2021 | 2.734B |
| September 30, 2021 | 2.779B |
| June 30, 2021 | 2.775B |
| March 31, 2021 | 2.694B |
| December 31, 2020 | 2.853B |
| September 30, 2020 | 3.376B |
| June 30, 2020 | 3.682B |
| March 31, 2020 | 3.534B |
| December 31, 2019 | 3.671B |
| September 30, 2019 | 3.600B |
| June 30, 2019 | 3.617B |
| March 31, 2019 | 3.490B |
| December 31, 2018 | 3.526B |
| September 30, 2018 | 3.439B |
| June 30, 2018 | 3.356B |
| March 31, 2018 | 3.131B |
| December 31, 2017 | 3.307B |
| Date | Value |
|---|---|
| September 30, 2017 | 3.078B |
| June 30, 2017 | 3.078B |
| March 31, 2017 | 2.811B |
| December 31, 2016 | 2.872B |
| September 30, 2016 | 2.956B |
| June 30, 2016 | 2.894B |
| March 31, 2016 | 2.727B |
| December 31, 2015 | 2.839B |
| September 30, 2015 | 2.778B |
| June 30, 2015 | 2.592B |
| March 31, 2015 | 2.555B |
| December 31, 2014 | 2.641B |
| September 30, 2014 | 2.511B |
| June 30, 2014 | 2.421B |
| March 31, 2014 | 2.130B |
| December 31, 2013 | 1.966B |
| September 30, 2013 | 1.828B |
| June 30, 2013 | 1.723B |
| March 31, 2013 | 1.415B |
| December 31, 2012 | 1.418B |
| September 30, 2012 | 1.386B |
| June 30, 2012 | 1.421B |
| March 31, 2012 | 1.292B |
| December 31, 2011 | 2.066B |
| September 30, 2011 | 1.043B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.386B
Minimum
Dec 2023
3.682B
Maximum
Jun 2020
2.912B
Average
2.734B
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 9.353B |
| Bristol-Myers Squibb Co | 11.48B |
| Gilead Sciences Inc | 7.114B |
| AbbVie Inc | 14.30B |
| Regeneron Pharmaceuticals Inc | 3.434B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 249.70M |
| Total Expenses (Quarterly) | 1.929B |
| EPS Diluted (Quarterly) | 1.71 |
| Enterprise Value | 33.97B |
| Gross Profit Margin (Quarterly) | 74.09% |
| Profit Margin (Quarterly) | 10.46% |
| Earnings Yield | 3.95% |
| Operating Earnings Yield | 6.23% |
| Normalized Earnings Yield | 5.505 |